Drug interactions
Doxorubicin liposomal + Lapatinib
Severity: Moderate
Doxorubicin liposomal and Lapatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lapatinib inhibits P-glycoprotein and CYP3A4, which may increase doxorubicin exposure. Liposomal formulation lessens but does not remove the risk of cardiotoxicity and myelosuppression, and lapatinib also carries cardiac risk.
What this interaction means in plain words
Doxorubicin liposomal and Lapatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Lapatinib inhibits P-glycoprotein and CYP3A4, reducing doxorubicin clearance; additive cardiotoxicity is also possible.
What to do
Monitor left ventricular ejection fraction and blood counts. Reduce the doxorubicin dose if toxicity develops.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Doxorubicin liposomal and Lapatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lapatinib
- Dofetilide + Lapatinib Contraindicated
- Ibutilide + Lapatinib Contraindicated
- Lapatinib + Pimozide Contraindicated
- Lapatinib + Saquinavir Contraindicated
- Lapatinib + Thioridazine Contraindicated
- Adagrasib + Lapatinib Major
Frequently asked questions
Can I take Doxorubicin liposomal with Lapatinib?
MediHelp rates the interaction as moderate. Doxorubicin liposomal and Lapatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lapatinib inhibits P-glycoprotein and CYP3A4, which may increase doxorubicin exposure. Liposomal formulation lessens but does not remove the risk of cardiotoxicity and myelosuppression, and lapatinib also carries cardiac risk.
How serious is the interaction between Doxorubicin liposomal and Lapatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor left ventricular ejection fraction and blood counts. Reduce the doxorubicin dose if toxicity develops.
What other medicines interact with Lapatinib?
MediHelp also lists interactions of Lapatinib with, for example, Dofetilide, Ibutilide, Pimozide. The full list is on the Lapatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
